Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis

Hidenori Takahashi, Shigetaka Shimodaira, Masahiro Ogasawara, Shuichi Ota, Masanori Kobayashi, Hirofumi Abe, Yuji Morita, Kazuhiro Nagai, Shunichi Tsujitani, Masato Okamoto, Yukio Suzuki, Yoichi Nakanishi, Yoshikazu Yonemitsu, the DC Vaccine Study Group at the Japanese Society of Immunotherapy for the DC Vaccine Study Group at the Japanese Society of Immunotherapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers. Methods: Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks. Results: The mean survival time (MST) from diagnosis was 33.0 months (95 % confidence interval [CI]: 27.9–39.2), and that from time of first vaccination was 13.8 months (95 % CI 11.4–16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 %, respectively, P = 0.014). Conclusions: This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.

Original languageEnglish
Pages (from-to)1099-1111
Number of pages13
JournalCancer Immunology, Immunotherapy
Volume65
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Cancer Vaccines
Non-Small Cell Lung Carcinoma
Dendritic Cells
Vaccines
Erythema
Survival
Vaccination
Adenocarcinoma
Survival Rate
Compassionate Use Trials
Confidence Intervals
Adenocarcinoma of lung
Pancreatic Neoplasms
Multicenter Studies
Randomized Controlled Trials
Peptides
Injections

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Takahashi, H., Shimodaira, S., Ogasawara, M., Ota, S., Kobayashi, M., Abe, H., ... for the DC Vaccine Study Group at the Japanese Society of Immunotherapy, T. DC. V. S. G. A. T. J. S. O. I. (2016). Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunology, Immunotherapy, 65(9), 1099-1111. https://doi.org/10.1007/s00262-016-1872-z

Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers : a multicenter retrospective analysis. / Takahashi, Hidenori; Shimodaira, Shigetaka; Ogasawara, Masahiro; Ota, Shuichi; Kobayashi, Masanori; Abe, Hirofumi; Morita, Yuji; Nagai, Kazuhiro; Tsujitani, Shunichi; Okamoto, Masato; Suzuki, Yukio; Nakanishi, Yoichi; Yonemitsu, Yoshikazu; for the DC Vaccine Study Group at the Japanese Society of Immunotherapy, the DC Vaccine Study Group at the Japanese Society of Immunotherapy.

In: Cancer Immunology, Immunotherapy, Vol. 65, No. 9, 01.09.2016, p. 1099-1111.

Research output: Contribution to journalArticle

Takahashi, H, Shimodaira, S, Ogasawara, M, Ota, S, Kobayashi, M, Abe, H, Morita, Y, Nagai, K, Tsujitani, S, Okamoto, M, Suzuki, Y, Nakanishi, Y, Yonemitsu, Y & for the DC Vaccine Study Group at the Japanese Society of Immunotherapy, TDCVSGATJSOI 2016, 'Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis' Cancer Immunology, Immunotherapy, vol. 65, no. 9, pp. 1099-1111. https://doi.org/10.1007/s00262-016-1872-z
Takahashi, Hidenori ; Shimodaira, Shigetaka ; Ogasawara, Masahiro ; Ota, Shuichi ; Kobayashi, Masanori ; Abe, Hirofumi ; Morita, Yuji ; Nagai, Kazuhiro ; Tsujitani, Shunichi ; Okamoto, Masato ; Suzuki, Yukio ; Nakanishi, Yoichi ; Yonemitsu, Yoshikazu ; for the DC Vaccine Study Group at the Japanese Society of Immunotherapy, the DC Vaccine Study Group at the Japanese Society of Immunotherapy. / Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers : a multicenter retrospective analysis. In: Cancer Immunology, Immunotherapy. 2016 ; Vol. 65, No. 9. pp. 1099-1111.
@article{7050d3c10f7d44df9c1372b8c3b93568,
title = "Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis",
abstract = "Objective: The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers. Methods: Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks. Results: The mean survival time (MST) from diagnosis was 33.0 months (95 {\%} confidence interval [CI]: 27.9–39.2), and that from time of first vaccination was 13.8 months (95 {\%} CI 11.4–16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 {\%}, respectively, P = 0.014). Conclusions: This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.",
author = "Hidenori Takahashi and Shigetaka Shimodaira and Masahiro Ogasawara and Shuichi Ota and Masanori Kobayashi and Hirofumi Abe and Yuji Morita and Kazuhiro Nagai and Shunichi Tsujitani and Masato Okamoto and Yukio Suzuki and Yoichi Nakanishi and Yoshikazu Yonemitsu and {for the DC Vaccine Study Group at the Japanese Society of Immunotherapy}, {the DC Vaccine Study Group at the Japanese Society of Immunotherapy}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s00262-016-1872-z",
language = "English",
volume = "65",
pages = "1099--1111",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "9",

}

TY - JOUR

T1 - Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers

T2 - a multicenter retrospective analysis

AU - Takahashi, Hidenori

AU - Shimodaira, Shigetaka

AU - Ogasawara, Masahiro

AU - Ota, Shuichi

AU - Kobayashi, Masanori

AU - Abe, Hirofumi

AU - Morita, Yuji

AU - Nagai, Kazuhiro

AU - Tsujitani, Shunichi

AU - Okamoto, Masato

AU - Suzuki, Yukio

AU - Nakanishi, Yoichi

AU - Yonemitsu, Yoshikazu

AU - for the DC Vaccine Study Group at the Japanese Society of Immunotherapy, the DC Vaccine Study Group at the Japanese Society of Immunotherapy

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective: The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers. Methods: Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks. Results: The mean survival time (MST) from diagnosis was 33.0 months (95 % confidence interval [CI]: 27.9–39.2), and that from time of first vaccination was 13.8 months (95 % CI 11.4–16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 %, respectively, P = 0.014). Conclusions: This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.

AB - Objective: The J-SICT DC Vaccine Study Group provides dendritic cell (DC) vaccines for compassionate use under unified cell production and patient treatment regimens. We previously reported beneficial effects of DC vaccines on the overall survival of 62 patients with advanced non-small cell lung cancer (NSCLC) in a single-center analysis. Here, we extended analysis to 260 patients with NSCLC who were treated at six centers. Methods: Of the 337 patients who met the inclusion criteria, we analyzed 260 patients who received ≥5 peptide-pulsed DC vaccinations once every 2 weeks. Results: The mean survival time (MST) from diagnosis was 33.0 months (95 % confidence interval [CI]: 27.9–39.2), and that from time of first vaccination was 13.8 months (95 % CI 11.4–16.8). An erythema reaction at the injection site that was ≥30 mm in diameter was correlated most strongly with overall survival from the first vaccine (≥30 vs. < 30 mm: MST 20.4 vs. 8.8 months, P < 0.001). We reported a similar finding in our previous analysis of patients with advanced pancreatic cancer. Interestingly, although such findings were common between patients with adenocarcinoma and those with other subtypes, the former group experienced significantly prolonged overall survival and a higher response rate for erythema (56.3 vs. 37.3 %, respectively, P = 0.014). Conclusions: This is the first multicenter study that suggests a possible clinical benefit of DC vaccines for patients with advanced NSCLC, especially those with adenocarcinoma. These findings suggest a specific potential responder population for DC vaccines and warrant further investigation in well-controlled prospective randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=84979287775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979287775&partnerID=8YFLogxK

U2 - 10.1007/s00262-016-1872-z

DO - 10.1007/s00262-016-1872-z

M3 - Article

VL - 65

SP - 1099

EP - 1111

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 9

ER -